<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739204</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH102-REC1-071</org_study_id>
    <nct_id>NCT02739204</nct_id>
  </id_info>
  <brief_title>Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma</brief_title>
  <official_title>Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health and Welfare, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research and development of novel anti-tumor agents in oral cancer is slow, the
      investigation of repositioning use of currently available drugs in clinical, such as a
      selective cyclooxygenase-2 (COX-2) inhibitor (Celebrex/Celecoxib) maybe a potential
      alternative strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Celebrex (Celecoxib) is a form of non-steroidal anti-inflammatory drug that directly targets
      COX-2 enzyme to block the inflammatory signaling and has been approved to treat colon cancer.
      In our preliminary findings, Celecoxib significantly inhibited cell growth,proliferation,
      migration, invasion and epithelial-mesenchymal transition programs in oral squamous cell
      carcinoma cell (OSCC) lines. The Institutional Review Board in China Medical University
      Hospital (CMUH) has approved the combination treatment of concurrent radiotherapy (RT) and/or
      Cisplatin with or without Celecoxib in a phase II clinical trial for relapse-free primary
      OSCC patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free recurrence</measure>
    <time_frame>3 year relapse-free recurrence</time_frame>
    <description>3-year follow-up after 6-month treatment of Celecoxib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>3 year relapse-free survival</time_frame>
    <description>3-year follow-up after 6-month treatment of Celecoxib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Oral Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. OSCC patients with T1,2/ N0 and without pathological risk features

          2. OSCC patients with T1,2/ N0,1 and pathological risk features

          3. OSCC patients with T4a/ N2,3

        Exclusion Criteria:

          1. Pregnant women paitents

          2. Taiwanese aboriginal patients

          3. Not primary OSCC patients

          4. OSCC patients with dysfunction of liver and/or kidneys
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying-Chin Ko, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Graduate Institute of Clinical Medical Science, China Medical University, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying-Chin Ko, MD-PhD</last_name>
    <phone>886-4-22052121</phone>
    <phone_ext>7322</phone_ext>
    <email>ycko0406@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Otolaryngology</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Hsul Tsai, M.D. Ph.D.</last_name>
      <phone>886-4-22052121</phone>
      <phone_ext>4436</phone_ext>
      <email>minghsui@mail.cmuh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chun-Hung Hua, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Celecoxib</keyword>
  <keyword>Relapse-free OSCC patient</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Survival</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

